Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
Adjuvants enhance antibody response against vaccination. We compared the ability of MF59-adjuvanted and non-adjuvanted subunit influenza vaccines, containing A/Wyoming/3/03(H3N2), to confer cross-protection against four consecutive drifted strains in the elderly. Neutralizing and haemagglutination-inhibiting antibody were measured. MF59-adjuvanted vaccine induced a stronger booster response against A/Panama/2007/99(H3N2) than non-adjuvanted vaccine. A/Panama/2007/99(H3N2) circulated widely during the previous 5 years and was included in vaccines over four consecutive seasons. Broader serological protection against drifted strains that circulated 1 and 2 years after vaccination with A/Wyoming/3/03(H3N2) was observed with MF59-adjuvanted vaccine. Thus, MF59-adjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations.
Ansaldi
Filippo
F
CIRI-IV, Department of Health Sciences, University of Genoa, Genoa, Italy. filippo.ansaldi@unige.it
Bacilieri
Sabrina
S
Durando
Paolo
P
Sticchi
Laura
L
Valle
Laura
L
Montomoli
Emanuele
E
Icardi
Giancarlo
G
Gasparini
Roberto
R
Crovari
Pietro
P
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis; D003429:Cross Reactions; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology / Q000627:therapeutic use*; D008875:Middle Aged; D009500:Neutralization Tests; D011136:Polysorbates / Q000494:pharmacology*; D013185:Squalene / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene